Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025)

Altimmune (ALT) posted quarterly Long-Term Debt Issuances of $20.0 million for Q4 2025, up 18936.38% quarter-over-quarter from $105062.0 in Q4 2019.

Analysis

Altimmune (ALT) Long-Term Debt Issuances (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Long-Term Debt Issuances for 8 consecutive years, with $20.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $20.0 million; the TTM figure through Dec 2025 stood at $20.0 million (changed N/A YoY), while the FY2025 annual figure was $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances improved to $20.0 million in Q4 2025 per ALT's latest filing, from $105062.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $20.0 million in Q4 2025 and bottomed at $20.0 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Altimmune	636.07 Mn	636.07 Mn	-	-

Historic Data

Download Data